With results coming so soon on Rett and alz, it would be irresponsible to accept any offer before then, and I am sure Missling would make that clear in private discussions, so Biogen "jumping" is very unlikely.
Biogen lost $20 billion in market value when its alz treatment failed. Therefore, if 273 is approved for alz, and Rett is approved, in addition to MS, the bidding should start at $10 billion minimum.
Market Data 
Markets 
AI
